AMG 334

Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention

by News Hour Correspondent - Jun 24, 2017

News Hour: Novartis announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for AMG 334 (erenumab) for the prevention of a migraine. Erenumab is an anti-CGRP monoclonal antibody developed to prevent a...
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334

by News Hour Correspondent - Apr 30, 2017

News Hour: Novartis announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of a migraine. This agreement builds on a 2015 global collaboration between Novartis and Amgen,...

Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention